The introduction of vaccines against Measles, Mumps, Rubella (MMR), and Varicella (the “V” in MMRV vaccines) led to a drop in the incidence of these diseases by 89% (Varicella) and 99% (MMR). These effective vaccines are a core component in most pediatric immunization programs across the world. Hence, every time a new pediatric vaccine is added to the existing immunization schedule, clinical evidence must be provided that the newcomer does not adversely influence the immunogenic response to the MMRV-licensed vaccines. These required non-inferiority studies when vaccines are co-administered (known as concomitant vaccine testing) come with their own challenges.
When it comes to clinical trials, sample collection kits need to arrive on time, or precious samples will not be able to be tested within stability, meaning their data is irretrievably lost. Adverse weather events and other disruptions to the sample chain of transport represent a serious threat to specimen stability and data integrity.
To combat this threat, Covance has invested in a team of global logistics personnel who continually monitor shipments and potential transportation problems around the world, implementing contingency plans when necessary to maintain an extraordinary record of 99.9% on-time deliveries. Even when faced with the largest storm so far this year, Winter Storm Jonas, Covance delivered.
Is it possible to get more efficiency in your conventional and specialty tests while maintaining ongoing quality? ISO 15189:2012 accreditation answers this question by delivering a comprehensive approach to quality management in medical, central and referral laboratories. Not only can these standards ensure quality, but they can reduce your risk of costly delays and ultimately save money in your trials.
“It’s no surprise that sponsors are concerned about the risk of regulatory findings and increasingly requesting ISO-accredited labs,” said Paul Kirchgraber, Vice President and Global General Manager at Covance Central Laboratory Services. “They need a demonstration of increasing quality—and savings—across their outsource vendors. Adopting ISO 15189:2012 is a powerful way to highlight our broad quality standards that meet or exceed their expectations.”
Advancing vaccine and novel immunotherapeutic development requires focused, specialized expertise. If you are looking to reveal more efficiencies in your vaccine and novel immunotherapeutic testing strategy, consider these three best practices:
1. Apply resources specifically tailored to your development
As you advance your vaccine or novel immunotherapeutic, it’s crucial to match solutions to your needs so you make the most of your efforts. Our dedicated vaccine and novel immunotherapeutic experts offer a consultative approach to determine exactly how to meet your requirements and accelerate your program. Co-located under the same roof, our scientists and study managers assign you a single point of contact to help simplify communications and decision-making so you can concentrate on the next steps. Continue reading
Infectious diseases contribute to approximately 25% of global mortality and present critical healthcare challenges, especially in under-resourced countries. Recent research and development breakthroughs may help transform this situation. The industry is now leveraging novel analytical and bioinformatics technologies to better understand the biology and response to viral and bacteriological infections, and thereby develop more rapid and effective strategies for evaluating new therapeutic agents in clinical trials.
1. Applying lessons learned
Hepatitis C virus (HCV) therapeutics, frequently described as a breakthrough area in drug development, because it highlights the result of combining the biological understanding of disease and prioritizing appropriate resources to speed drug development. The first curative therapeutic regimens containing direct-acting agents for this important cause of liver disease were approved in 2011. Since then, seven additional regimens have received FDA approval with several more promising treatments currently in late stage clinical trials. Continue reading
Companion diagnostics are evolving quickly as novel technologies emerge and new drug targets appear. Dr. Mark Roberts, Director of Diagnostics Development, recently shared his thoughts on the industry trends ahead of the World CDx Boston 2015.
How much progress has been made in the area of companion diagnostics? Continue reading
Last month I was interviewed by ClinicalLeader for an article about how the central laboratory approach, as opposed to the traditional, distributed model of clinical trial lab testing, is driving higher quality and efficiency in clinical drug development. The article highlighted Covance Central Laboratory Services (Covance CLS) as an example for the new model emerging – using advanced technologies and global operations to concentrate all clinical trial tests into a single, central laboratory. The article also addressed how and why the industry is beginning to adopt central laboratory services for oncology studies. Continue reading